

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	Amended and Restated Assginnment of 50% Interest to Enzon Pharmaceuticals, Inc. effective July 26, 2006
CONVEYING PARTY DATA	
Name	Execution Date
Santaris Pharma A/S	03/25/2009
RECEIVING PARTY DATA	
Name:	Enzon Pharmaceuticals, Inc.
Street Address:	685 Route 202/206
City:	Bridgewater
State/Country:	NEW JERSEY
Postal Code:	08807
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	11271686
CORRESPONDENCE DATA	
Fax Number:	(212)698-3599
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	2126983500
Email:	donna.tirella@dechert.com
Correspondent Name:	Dechert LLP
Address Line 1:	P.O. Box 390460
Address Line 4:	Mountain View, CALIFORNIA 94039-0460
ATTORNEY DOCKET NUMBER:	366929-025US (396542)
NAME OF SUBMITTER:	Donna M. Tirella
Total Attachments: 2 source=025US-Assignment#page1.tif source=025US-Assignment#page2.tif	

CH \$40.00 11271686

500827010

PATENT
REEL: 022505 FRAME: 0620

AMENDED AND RESTATED ASSIGNMENT AGREEMENT

WHEREAS, Santaris Pharma A/S, a Danish corporation having an office and a place of business at Kogle Allé 6, DK-2970, Hørsholm, Denmark ("Santaris") and Enzon Pharmaceuticals, Inc. f/k/a Enzon Inc., a Delaware Corporation having a principal place of business at 685 Route 202/206, Bridgewater, NJ 08807, United States ("Enzon") entered into a License and Collaboration Agreement dated July 26, 2006 (the "Collaboration Agreement");

WHEREAS, pursuant to Article 8 of the Collaboration Agreement, effective as of July 26, 2006, Santaris assigned to Enzon an undivided one-half (50%) right, title and interest in the Assigned Patents (defined below), without the need for any further action by any party; and

WHEREAS, the parties executed and recorded certain assignment agreements relating to the Assigned Patents dated respectively as of March 22, 2007 (the "March 2007 Agreement") and August 21, 2007 (the "August 2007 Agreement"), which agreements contain certain errors, and the parties desire to revoke and nullify such agreements.

NOW THEREFORE, be it known that for and in consideration of the sum of One Dollar (\$1.00) and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows:

1. Each of the March 2007 Agreement and the August 2007 Agreement is hereby revoked and null and void *nunc pro tunc*. This Amended and Restated Assignment Agreement is intended to amend and supersede each of the March 2007 Agreement and the August 2007 Agreement in its entirety.
2. Santaris and Enzon hereby confirm and agree that, effective as of July 26, 2006, Santaris assigned to Enzon, its successors and assigns, and Enzon accepted on behalf of itself and its successors and assigns, an undivided one-half (50%) right, title and interest in and to the patent application entitled "Potent LNA Oligonucleotides for the Inhibition of HIF-1A Expression", said application being identified as U.S. patent application serial number 11/271,686 filed on November 9, 2005 together with any other patents issuing in the United States from the foregoing, including without limitation any division, substitution, continuation, continuation-in-part, reissue, reexamination or extension (collectively, the "Assigned Patents").
3. Santaris has agreed to execute upon request of Enzon, and at Enzon's expense, such additional documents, if any, as are necessary and proper to secure patent protection on the Assigned Patents in the United States, and to otherwise give full effect to and perfect the rights of Enzon under the Collaboration Agreement.

IN WITNESS WHEREOF, the parties have executed this Amended and Restated Assignment Agreement on the date indicated hereinafter.

Santaris Pharma /S

By:

Name:

Maja Bojko

Title:

Director IP

Date

H. B. Shofar 25/3-09

Witnessed by:

Name:

SANTARIS PHARMA

TAMMY BOGSTRAND

Date

H. B. Shofar 25/3-2009

Enzon Pharmaceuticals, Inc.

By:

Name:

Title:

Margaret Albanese

Director, Intellectual Property

Date

April 1, 2009

Witnessed by:

Name:

Carol Smith

CAROL SMITH

Date

April 1, 2009

14952484 1 BUSINESS

PATENT

RECORDED: 04/05/2009

REEL: 022505 FRAME: 0622